Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment

Drug and Alcohol Dependence

Volumn 136, Issue 1, 2014, Pages 36-42

  Schottenfeld, Richard S ^a   Chawarski, Marek C ^a   Cubells, Joseph F ^b   George, Tony P ^c   Lappalainen, Jaakko ^a   Kosten, Thomas R ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Buprenorphine pharmacogenetics; Cocaine abuse or dependence; DBH genotype; Disulfiram

Indexed keywords

BUPRENORPHINE PHARMACOGENETICS; COCAINE ABUSE OR DEPENDENCE; DBH GENOTYPE; DISULFIRAM;

ADOLESCENT; ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; ALLELES; BUPRENORPHINE; COCAINE-RELATED DISORDERS; DATA INTERPRETATION, STATISTICAL; DISULFIRAM; DNA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; SAMPLE SIZE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893746282     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.12.007     Document Type: Article

References (56)

1. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. American Psychiatric Publishing, Washington, DC.
2. Arfken C.L., Johanson C.E., di Menza S., Schuster C.R. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J. Subst. Abuse Treat. 2010, 39:96-104.
3. Baker J.R., Jatlow P., McCance-Katz E.F. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007, 87:202-209.
4. Bourdélat-Parks B.N., Anderson G.M., Donaldson Z.R., Weiss J.M., Bonsall R.W., Emery M.S., Liles L.C., Weinshenker D. Effects of dopamine β-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychophamacology 2005, 183:72-80.
5. Bux D.A., Lamb R.J., Iguchi M.Y. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend. 1995, 37:29-35.
6. Carroll K., Ziedonis D., O'Malley S.S., McCance-Katz E., et al. Pharmacologic interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. Am. J. Addict. 1993, 2:77-79.
7. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., Rounsaville B.J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry 2004, 61:264-272.
8. Carroll K.M., Nich C., Ball S.A., McCance E., Rounsavile B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998, 93:713-727.
9. Chaisson R.E., Bacchetti P., Osmond D., et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989, 261:561-565.
10. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Safety 1999, 20:427-435.
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
12. Cubells J.F., Kranzler H.R., McCance-Katz E., Anderson G.M., Malison R.T., Price L.H., Gelernter J. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry 2000, 5:56-63.
13. Enghusen Poulsen H., Loft S., Andersen J.R., Andersen M. Disulfiram therapy--adverse drug reactions and interactions. Acta Psychiatrica Scand. Suppl. 1992, 369:59-65.
14. Ewing J.A., Mueller R.A., Rouse B.A., Silver D. Low levels of dopamine beta-hydroxylase and psychosis. Am. J. Psychiatry 1977, 134:927-928.
15. Ewing J.A., Rouse B.A., Mueller R.A., Silver D. Can dopamine beta-hydroxylase levels predict adverse reactions to disulfiram?. Alcohol. Clin. Exp. Res. 1978, 2:93-94.
16. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., Barry D.T., O'Connor P.G., Schottenfeld R.S. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am. J. Addict. 2008, 17:116-120.
17. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., Schottenfeld R.S. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 2006, 355:365-374.
18. George T.P., Chawarski M.C., Pakes J., Carroll K.M., Kosten T.R., Schottenfeld R.S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol. Psychiatry 2000, 47:1080-1086.
19. Goldstein M., Anagoste B., Lauber E., McKereghan M.R. Inhibition of dopamine beta-hydroxylase by disulfiram. Life Sci. 1964, 3:763-767.
20. Haddad M.S., Zelenev A., Altice F.L. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013, 131:127-135.
21. Hameedi F.A., Rosen M.I., McCance-Katz E.F., McMahon T.J., Price L.H., Jatlow P.I., Woods S.W., Kosten T.R. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol. Psychiatry 1995, 37:560-563.
22. Hartel D.M., Schoenbaum E.E., Selwyn P.A., Kline J., Davenny K., Klein R.S., Friedland G.H. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am. J. Public Health 1995, 85:83-88.
23. Hubbard R.L., Craddock S., Flynn P.M., Anderson J., Etheridge R.M. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol. Addict. Behav. 1997, 11:261-278.
24. Hunt D., Spunt B., Lipton D. The costly bonus: Cocaine related crime among methadone treatment clients. Adv. Alcohol Subst. Abuse 1986, 6:107-122.
25. Joe G.W., Simpson D.D. HIV risks, gender, and cocaine use among opiate users. Drug Alcohol Depend. 1995, 37:23-28.
26. Kalayasiri R., Sughondhabirom A., Gueorguieva R., Coric V., Lynch W.J., Lappalainen J., Gelernter J., Cubells J.F., Malison R.T. Dopamine beta-hydroxylase gene (DbetaH) -1021C-->T influences self-reported paranoia during cocaine self-administration. Biol. Psychiatry 2007, 61:1310-1313.
27. Karamanakos P.N., Pappas P., Stephanou P., Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol. Toxicol. 2001, 88:106-110.
28. Kolar A.F., Brown B.S., Weddington W.W. A treatment crisis: cocaine use by clients in methadone maintenance programs. J. Subst. Abuse Treat. 1990, 7:101-107.
29. Kosten T.R., Rounsaville B.J., Kleber H.D. A 2.5 year follow-up of cocaine use among treated opioid addicts. Arch. Gen. Psychiatry 1987, 44:281-284.
30. Kosten T.R., Rounsaville B.J., Kleber H.D. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J. Nerv. Ment. Dis. 1988, 176:176-181.
31. Kosten T.R., Wu G., Huang W., Harding M.J., Hamon S.C., Lappalainen J., Nielsen D.A. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-Hydroxylase. Biol. Psychiatry 2012, 73:219-224.
32. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991, 19:5444.
33. Leri F., Bruneau J., Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003, 98:7-22.
34. Major L.F., Lerner P., Ballenger J.C., Brown G.L., Goodwin F.K., Lovenberg W. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol. Psychiatry 1979, 14:337-344.
35. Mattick, R.P., Kimber, J., Breen, C., Davoli, M., 2003. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. Issue 2. Art. No.: CD002207. DOI:10.1002/14651858.CD002207.pub2, 3.
36. Mays D.C., Ortiz-Bermudez P., Lam J.P., Tong I.H., Fauq A.H., Lipsky J.J. Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram. Biochem. Pharmacol. 1998, 55:1099-1103.
37. McCance-Katz E.F., Kosten T.R., Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol. Psychiatry 1998, 43:540-543.
38. McCance-Katz E.F., Kosten T.R., Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 1998, 52:27-39.
39. Mercer D.E., Woody G.E. An Individual Drug Counseling Approach to Treat Cocaine Addiction: The Collaborative Cocaine Treatment Study Model 1999, National Institutes of Health.
40. Mutschler J., Diehl A., Kiefer F. Pronounced paranoia as a result of cocaine-disulfiram interaction: case report and mode of action. J. Clin. Psychopharmacol. 2009, 29:99-101.
41. Oliveto A., Poling J., Mancino M.J., Feldman Z., Cubells J.F., Pruzinsky R., Gonsai K., Cargile C., Sofuoglu M., Chopra M.P., Gonzalez-Haddad G., Carroll K.M., Kosten T.R. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011, 113:184-191.
42. Pani P., Trougu E., Vacca R., Amato L., Vecchi S., Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst. Rev. 2010, 1.
43. Petrakis I.L., Carroll K.M., Nich C., Gordon L.T., McCance-Katz E.F., Frankforter T., Rounsaville B.J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000, 95:219-228.
44. Schank J.R., Liles L.C., Weinshenker D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol. Psychiatry 2008, 63:1007-1012.
45. Schank J.R., Ventura R., Puglisi-Allegra S., Alcaro A., Cole C.D., Liles L.C., Seeman P., Weinshenker D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 2006, 31:2221-2230.
46. Schroeder J.P., Cooper D.A., Schank J.R., Lyle M.A., Gaval-Cruz M., Ogbonmwan Y.E., Pozdeyev N., Freeman K.G., Iuvone P.M., Edwards G.L., Holmes P.V., Weinshenker D. Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase. Neuropsychopharmacology 2010, 35:2440-2449.
47. Sobell L.C., Sobell M.B., Riley D.M., Schuller R., Pavan D.S., Cancilla A., Klajner F., Leo G.I. The reliability of alcohol abusers' self-reports of drinking and life events that occurred in the distant past. J. Stud. Alcohol 1988, 49:225-232.
48. Sobell M.B., Sobell L.C., Klajner F., Pavan D., Basian E. The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict. Behav. 1986, 11:149-161.
49. Sofuoglu M., Poling J., Waters A., Sewell A., Hill K., Kosten T. Disulfiram enhances subjective effects of dextroamphetamine in humans. Pharmacol. Biochem. Behav. 2008, 90:394-398.
50. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III--R (SCID): I. History, rationale, and description. Arch. Gen. Psychiatry 1992, 49:624-629.
51. Stanley W.C., Li B., Bonhaus D.W., Johnson L.G., Lee K., Porter S., Walker K., Martinez G., Eglen R.M., Whiting R.L., Hegde S.S. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br. J. Pharmacol. 1997, 121:1803-1809.
52. Substance Abuse and Mental Health Services Administration, 2008. Results from the 2007 National Survey on Drug Use and Health: National Findings. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD.
53. Wasserman D.A., Weinstein M.G., Havassy B.E., Hall S.M. Factors associated with relapses to heroin use during methadone maintenance. Drug Alcohol Depend. 1998, 52:183-192.
54. Weinshenker D. Cocaine sobers up. Nat. Med. 2010, 16:969-970.
55. Yao L., Fan P., Arolfo M., Jiang Z., Olive M.F., Zablocki J., Sun H.L., Chu N., Lee J., Kim H.Y., Leung K., Shryock J., Blackburn B., Diamond I. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat. Med. 2010, 16:1024-1028.
56. Zabetian C.P., Anderson G.M., Buxbaum S.G., Elston R.C., Ichinose H., Nagatsu T., Kim K.S., Kim C.H., Malison R.T., Gelernter J., Cubells J.F. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 2001, 68:515-522.